首页> Current treatment options in oncology> BRAF-Mutated Colorectal Cancer: What Is the Optimal Strategy for Treatment?

BRAF-Mutated Colorectal Cancer: What Is the Optimal Strategy for Treatment?

导出原文传递

翻译打印收藏纠错

第一作者： Romain,Cohen

第一单位： Department of Medical Oncology, Saint-Antoine Hospital, APHP, 184 rue du Faubourg Saint-Antoine, 75012, Paris, France.

作者： Romain,Cohen ^[1] ; Pascale,Cervera ^[2] ; Magali,Svrcek ^[2] ; Anna,Pellat ^[1] ; Chantal,Dreyer ^[1] ; Aimery,de Gramont ^[3] ; Thierry,André ^[4]

作者单位： Department of Medical Oncology, Saint-Antoine Hospital, APHP, 184 rue du Faubourg Saint-Antoine, 75012, Paris, France. ^[1] Department of Pathology, Saint-Antoine Hospital, APHP, 184 rue du Faubourg Saint-Antoine, 75012, Paris, France. ^[2] Department of Medical Oncology, Institut Hospitalier Franco-Britannique, 4 rue Kléber, 92300, Levallois-Perret, France.;GERCOR, Oncology Multidisciplinary Group, 151 rue du Faubourg Saint Antoine, 75011, Paris, France. ^[3] Department of Medical Oncology, Saint-Antoine Hospital, APHP, 184 rue du Faubourg Saint-Antoine, 75012, Paris, France. thierry.andre@aphp.fr.;GERCOR, Oncology Multidisciplinary Group, 151 rue du Faubourg Saint Antoine, 75011, Paris, France. thierry.andre@aphp.fr. ^[4]

关键词 BRAFV600E Checkpoint inhibitor Colorectal cancer Dabrafenib FOLFOXIRI Microsatellite instability Vemurafenib